BioWorld

May 11, 2009

Exelixis, BI Enter Autoimmune Agreement Worth up to $354M

Exelixis Inc. and German drugmaker Boehringer Ingelheim GmbH entered a deal potentially worth $354 million to discover, develop and commercialize autoimmune disease therapies. (BioWorld Today) Read More

Biotech Clusters Face Challenges, but Jobs and Capital Still Exist

H1N1 Swine, H5N1 Bird Flu Both Still Long Way from Pandemic

Dendreon Offering Raises $230M for Provenge Launch Preparation

CDC: H1N1 Bullet Not Dodged Just Yet, Threat not Over

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...